{"title":"Helex Septal Occluder for Closure of Atrial Septal Defects.","authors":"Latson, Zahn, Wilson","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The HELEX Septal Occluder (W.L. Gore and Associates, Flagstaff, AZ) is a new device with many desirable characteristics. These include direct placement of the delivery catheter across the septal defect without the need for a long sheath; rounded, flexible and atraumatic shape; easy deployment while maintaining the ability to withdraw the device back into the delivery system at any time prior to release; safety cord to allow for removal of the device even after release from the formed elements of the delivery system; and highly biocompatible expanded polytetrafluoroethylene (ePTFE) covering. The design of the device has been thoroughly tested by computer modeling, in vitro testing, and in vivo evaluations in an animal model of atrial septal defect (ASD). Early human experience in Europe for ASD and patent foramen ovale (PFO) indications has been encouraging. Food and Drug Administration (FDA) trials in the United States are anticipated this year.</p>","PeriodicalId":80270,"journal":{"name":"Current interventional cardiology reports","volume":"2 3","pages":"268-273"},"PeriodicalIF":0.0000,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current interventional cardiology reports","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The HELEX Septal Occluder (W.L. Gore and Associates, Flagstaff, AZ) is a new device with many desirable characteristics. These include direct placement of the delivery catheter across the septal defect without the need for a long sheath; rounded, flexible and atraumatic shape; easy deployment while maintaining the ability to withdraw the device back into the delivery system at any time prior to release; safety cord to allow for removal of the device even after release from the formed elements of the delivery system; and highly biocompatible expanded polytetrafluoroethylene (ePTFE) covering. The design of the device has been thoroughly tested by computer modeling, in vitro testing, and in vivo evaluations in an animal model of atrial septal defect (ASD). Early human experience in Europe for ASD and patent foramen ovale (PFO) indications has been encouraging. Food and Drug Administration (FDA) trials in the United States are anticipated this year.
HELEX室间隔闭塞器(W.L. Gore and Associates, Flagstaff, AZ)是一种具有许多理想特性的新设备。这些方法包括直接放置导管穿过间隔缺损而不需要长鞘;外形圆润、灵活、自然;易于部署,同时保持在释放之前的任何时间将设备撤回到交付系统中的能力;安全绳,即使在从输送系统的成型元件中释放后,也可以将设备移除;和高度生物相容性膨胀聚四氟乙烯(ePTFE)覆盖物。该装置的设计已经通过计算机建模、体外测试和房间隔缺损(ASD)动物模型的体内评估进行了彻底的测试。在欧洲,ASD和卵圆孔未闭(PFO)适应症的早期人类经验令人鼓舞。美国食品和药物管理局(FDA)预计今年将在美国进行试验。